Discontinuing aspirin therapy and administering low-dose colchicine on the day after percutaneous coronary intervention (PCI) in addition to ticagrelor or prasugrel P2Y12 inhibitors is associated with benefits for platelet function and inflammatory profiles in acute coronary syndrome (ACS) patients, new trial data suggest.